Cargando…

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Background: In progressive multiple sclerosis (MS), glial activation is thought to be a relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the emerging treatment era of primary progressive MS (PPMS), more important than ever. Objectives: To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelhak, Ahmed, Hottenrott, Tilman, Morenas-Rodríguez, Estrella, Suárez-Calvet, Marc, Zettl, Uwe K., Haass, Christian, Meuth, Sven G., Rauer, Sebastian, Otto, Markus, Tumani, Hayrettin, Huss, André
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443875/ https://www.ncbi.nlm.nih.gov/pubmed/30972011 http://dx.doi.org/10.3389/fneur.2019.00280

Ejemplares similares

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Serum GFAP as a biomarker for disease severity in multiple sclerosis
por: Abdelhak, A., et al.
Publicado: (2018)

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis
por: Abdelhak, A., et al.
Publicado: (2019)

Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease
por: Huss, André, et al.
Publicado: (2022)

Development of an ultrasensitive microfluidic assay for the analysis of Glial fibrillary acidic protein (GFAP) in blood
por: Fazeli, Badrieh, et al.
Publicado: (2023)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
por: Robinson, Tilman, et al.
Publicado: (2020)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2019)

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
por: Huss, André, et al.
Publicado: (2020)

Discrepancy in the Usage of GFAP as a Marker of Satellite Glial Cell Reactivity
por: Mohr, Kjeld Morten, et al.
Publicado: (2021)

CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort
por: Senel, Makbule, et al.
Publicado: (2019)

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity
por: Ayrignac, Xavier, et al.
Publicado: (2020)

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
por: Abdelhak, Ahmed, et al.
Publicado: (2015)

Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β
por: Hesse, Raphael, et al.
Publicado: (2016)

Expression of radial glial markers (GFAP, BLBP and GS) during telencephalic development in the catshark (Scyliorhinus canicula)
por: Docampo-Seara, A., et al.
Publicado: (2018)

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Petereit, Hela-Felicitas, et al.
Publicado: (2021)

CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia
por: Woollacott, Ione O. C., et al.
Publicado: (2022)

CSF and Blood Levels of GFAP in Alexander Disease
por: Jany, Paige L., et al.
Publicado: (2015)

Beyond the GFAP-Astrocyte Protein Markers in the Brain
por: Jurga, Agnieszka M., et al.
Publicado: (2021)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults
por: Huebschmann, Nathan A., et al.
Publicado: (2020)

Ultrasensitive Determination of Glial-Fibrillary-Acidic-Protein (GFAP) in Human Serum-Matrix with a Label-Free Impedimetric Immunosensor
por: Ozcelikay, Goksu, et al.
Publicado: (2022)

Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology
por: Cuomo-Haymour, Nagiua, et al.
Publicado: (2022)

Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2022)

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases
por: Abu-Rumeileh, Samir, et al.
Publicado: (2020)

Serum Glial Fibrillary Acidic Protein: A Surrogate Marker of the Activity of Multiple Sclerosis
por: Sharquie, Inas K., et al.
Publicado: (2020)

Rab6A as a Pan-Astrocytic Marker in Mouse and Human Brain, and Comparison with Other Glial Markers (GFAP, GS, Aldh1L1, SOX9)
por: Melzer, Linda, et al.
Publicado: (2021)

GFAP and Neuron Specific Enolase (NSE) in the Serum of Suicide Attempters
por: Bagheri, Maryam, et al.
Publicado: (2022)

The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP
por: Lin, Ni-Hsuan, et al.
Publicado: (2016)

Serum Glial Fibrillary Acidic Protein as a Specific Marker for Necrotizing Meningoencephalitis in Pug Dogs
por: MIYAKE, Hizuru, et al.
Publicado: (2013)

The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis
por: Dersch, R, et al.
Publicado: (2015)

Signatures of glial activity can be detected in the CSF proteome
por: Eninger, Timo, et al.
Publicado: (2022)

Glial Fibrillary Acidic Protein (GFAP) as a Mesenchymal marker of Early Hepatic Stellate Cells Activation in Liver Fibrosis in Chronic Hepatitis C Infection
por: Hassan, Sobia, et al.
Publicado: (2014)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Oligodendrocyte Lineage Marker Expression in eGFP-GFAP Transgenic Mice
por: Behrangi, Newshan, et al.
Publicado: (2020)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients
por: Ren, Changhong, et al.
Publicado: (2016)

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
por: Ewers, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_smaiakap0007efhd8ng2sj8a2l